Results 121 to 130 of about 13,388,853 (301)
Andrology, EarlyView.ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul +3 more
wiley +1 more source
Screening Emodin Derivatives as DPP-4 Inhibitor Candidates: In Silico and In Vitro Assessment [PDF]
Diabetes mellitus (DM) is a chronic metabolic disease distinguished by disrupted glucose metabolism, causing elevated blood sugar levels. One of the latest therapeutic strategies involves inhibiting dipeptidyl peptidase-4 (DPP-4) to regulate glucose ...
Syahbirin, Gustini +3 more
core +1 more source
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
Andrology, EarlyView.ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source
Role of DPP-4 inhibitors in the treatment of type 2 Diabetes
, 2014 Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral anti-hyperglycaemic medication which enhance insulin secretion. They are considered to be a promising drug class that may meet the demands for efficacy in the treatment of type ...
Nguyen, Khanh Minh
core
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
, 2016 Diabetes mellitus (DM) is a chronic disease which caused around 1.5 million deaths in 2012. Type 2 diabetes mellitus (T2DM) accounts for 90% of DM worldwide. The prevalence of T2DM is increasing due to obesity.
Kristin, Erna
core +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi +9 more
wiley +1 more source
International Journal for Research Trends and Innovation, 2023 Purvita Laxman waghmodey +2 more
openaire +1 more source
Lactobacilli possess inhibitory activity against dipeptidyl peptidase-4 (DPP-4)
, 2015 Dipeptidyl peptidase 4 (DPP-4) enzymatically inactivates incretin hormones, and DPP-4 inhibitor drugs are clinically approved therapies for type 2 diabetes.
Panwar, Harsh +4 more
core +1 more source
Gut microbiota as a novel therapeutic target for eating disorders and obesity
British Journal of Pharmacology, EarlyView.The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė +5 more
wiley +1 more source
Alogliptin benzoate for management of type 2 diabetes
Vascular Health and Risk Management, 2015 Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj